Johnston SS, et al. - In this retrospective study, researchers examined the connection between body mass index (BMI) and insulin use with type 2 diabetes-related healthcare expenditures (T2D-HE). Study participants included 13,026 patients. Baseline insulin use rates ranged from 19.7% in overweight candidates to 33.0% in obese class III (OCIII) patients. Both BMI and insulin use were jointly linked to 1-year follow-up T2D-HE, which monotonically ranged from $5,842 in overweight patients with no insulin to $17,700 in OCIII insulin users. According to findings, BMI and use of insulin are simple stratifiers for high-cost patient identification. Because OCIII insulin users incurred the greatest annual healthcare expenditures, they might be an ideal group for targeted interventions.